Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses
|
|
- Eugene Harper
- 5 years ago
- Views:
Transcription
1 Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses HPFT Medicines Formulary lists the APDs that have been approved for use, however, it does not provide any detail on how these APDs should be selected. It is widely accepted that there is very little difference in efficacy between the approved APDs (except clozapine). However, there are notable differences in their side-effect profiles and more recently, due to patent expiries, significant variations in their cost (see graphs 1 and 2). When making prescribing decisions, clinicians are expected to take into account many factors including the cost impact an APD choice will have on the wider health economy. The algorithm below and table 1 include the important factors to be considered when selecting an APD for schizophrenia. Table 1 also lists the preferred APDs as they represent more cost-effective choices. APDs are also often used in the management of other mental health disorders and the same considerations should be applied when selecting an APD in these situations too. Clinicians should consider selecting APDs from the preferred list wherever possible, however it is recognised that the preferred APDs may not always be appropriate or meet the needs of every individual and second line alternative APD choices are therefore provided. Clinicians must ensure that there is a clear and valid rationale for selecting an alternative choice of APD and that this is documented and communicated to the relevant GPs when requesting continuation prescribing. Sufficient clinical information, including monitoring requirements must also be provided so that the GP can safely take on prescribing responsibility. See pg 6 for checklist of minimum information that must be provided to the GP. Antipsychotic Treatment Algorithm for Schizophrenia (Adapted from Maudsley Prescribing Guidelines in Psychiatry 11 th Edition) Choice of APD should be based on indication, product licensing, comorbidities, risk factors, likely benefits, side effect profile, cost, previous patient response and individual patient preference as well as other factors see table pg 2 and 3 Agree choice of APD from preferred list where possible with patient (and carer if appropriate). Include use of patient decision aids where possible. Titrate if necessary to minimum effective dose Adjust dose according to response and tolerability Assess over 2-3 weeks. Reassess partial responders at 6 to 8 weeks Effective Continue at dose established as effective. Once stable provide the GP with the necessary information to allow safe transfer of prescribing & monitoring responsibility Ineffective or not tolerated Change APD and follow above process Poor compliance Not tolerated Change APD and follow above process Effective Continue at dose established as effective. Once stable provide the GP with the necessary information to allow safe transfer of prescribing & monitoring responsibility Ineffective Consider clozapine in line with NICE CG 82 and SIGN 131 If poor adherence is related to poor tolerability, discuss with patient and change APD If poor adherence is related to other factors, consider APD depot/lai or compliance aids Page 1 of 6
2 Preferred APD choices and second line alternatives NICE CG 82 for Schizophrenia does not differentiate between choice of first and second generation antipsychotics. An oral APD should be offered first line unless patient prefers depot/lai after an acute episode, or when avoiding covert non-adherence to antipsychotic treatment is a clinical priority. HFPT Drugs and Therapeutics Committee has considered the SIGN 131 Guideline on management of schizophrenia, and concluded that the prescribing choices listed below are appropriate. First generation oral APDs are not drugs of choice ahead of second generation oral agents or first generation antipsychotic depots. Table 1 Antipsychotic Group Oral antipsychotics First generation (typical) (FGA) and Second generation (atypical) (SGA) Antipsychotic Depot (FGA) and Long Acting injections (LAI) (SGA) Preferred choices 2 nd line alternatives Prescribing Notes Haloperidol tablets (FGA), Olanzapine tablets (SGA), Quetiapine immediate release (IR) tablets (SGA), Risperidone tablets (SGA) Sulpiride tablets (FGA) Flupentixol decanoate (FGA), Fluphenazine decanoate (FGA), Haloperidol decanoate (FGA), Pipotiazine palmitate (FGA), Zuclopenthixol decanoate (FGA) All other FGAs listed in HPFT formulary Amisulpride tablets (SGA), Aripiprazole tablets (SGA), Quetiapine XL tablets (SGA), Clozapine tablets (SGA) Risperidone LAI (SGA), Paliperidone palmitate LAI (SGA) Second line alternatives should be considered when preferred choices are not appropriate. The rationale for selecting a second line preference must be valid, documented and clearly communicated to GP. All APDs should be prescribed by generic name. See side-effect table and cost comparison charts below to help guide choice of APD. Standard tablets are preferred. Orodispersible tablets and liquid formulations should only be used when clinically essential. Use cost chart to select the most cost-effective formulations. Quetiapine IR tablets must be used for all new patients. XL tablets may be used when initiating/titrating doses in acute situations however patients must be switched to IR tablets thereafter. XL tablets otherwise should only be used when IR tablets are not tolerated because of excessive sedation or non compliance with a twice daily regime. Rationale for XL must be documented and provided to GP. Clozapine to be considered for schizophrenia in those who have not responded to two APDs including a SGA. Clozapine prescribing to remain with HPFT. Olanzapine embonate LAI is not approved for use except on an individual named patient basis. Paliperidone oral is not approved for use. Paliperidone LAI is approved for use within licensed indications on a named patient basis when one or more of the following advantages of paliperidone (over risperidone) would be of significant benefit - monthly administration, quicker onset of action, 7 day flexibility to avoid missed doses, smaller administration volume, fewer drug interactions, wider dosing range and no dose adjustment required in mild to moderate hepatic impairment. Page 2 of 6 2
3 Antipsychotics relative side-effects The following table can be used by prescribers in conjunction with patients to help guide choice of APD. Alternatively the Choice and Medication website provides information for patients on medicines used in mental health. The handy chart comparing medicines used for psychosis is a more patient friendly resource which may be helpful when discussing potential benefits and harms of individual antipsychotics with patients. Please note the Choice and Medication website may include information on medicines that have not been approved in Hertfordshire. Preferred oral choices Haloperidol Olanzapine Quetiapine (IR) Risperidone Sulpiride 2nd Line alternative oral choices Amisulpride Aripiprazole Chlorpromazine Clozapine Flupentixol Promazine Trifluoperazine Zuclopenthixol Preferred Depot injections Flupenthixol Fluphenazine Haloperidol decanoate Pipotiazine Zuclopenthixol 2 nd Line Alternative Long acting injections Paliperidone Risperidone Consta marked effect moderate effect mild/ transient effect little or minimal effect no information available or little reported Reference: Stephen Bazire Psychotropic Drug Directory 2012 Page 3 of 6 3
4 Graph 1 - Antipsychotic comparative costs for 28 days treatment on maximum licensed doses. (Drug Tariff Sep 2013) (NB Doses quoted do not imply equivalence) Clozapine tabs (Denzapine ) 900mg/day Aripiprazole liquid 30mg/day Aripiprazole orodisp tabs 30mg/day Aripiprazole tabs 30mg/day Amisulpride liquid (Solian )1200mg/day Amisulpride liquid 1200mg/day Amisulpride (Solian )1200mg/day Amisulpride 1200mg/day Sulpiride liq (Sulpor ) 2400mg/day Sulpiride tabs 2400mg/day Sulpiride tabs (Dolmatil ) 2400mg/day Risperidone oral sol 16mg/day Risperidone liquid (Risperdal ) 16mg/day Risperidone orodisp (Risperdal Quicklets) 16mg/day Risperidone tabs (Risperdal ) 16mg/day Risperidone tabs 16mg/day 4.33 Quetiapine MR (Seroquel XL) tabs 800mg/day Quetiapine (Seroquel ) tabs 750mg/day Quetiapine tabs (Gen) 750mg/day Haloperidol liquid 30mg/day Haloperidol tabs 30mg/day Olanzapine velotabs (Zyprexa ) 20mg/day Olanzapine tabs (Zyprexa ) 20mg/day Olanzapine orodispersibe sugarfree (Gen) 20mg/day Olanzapine orodispersible (Gen) 20mg/day Olanzapine tabs (Gen) 20mg/day Preferred APD choice Premium priced preparations to be avoided/restricted 2nd line alternative choices 2nd line premium priced preparations to be avoided Page 4 of 6 4
5 Graph 2 - Antipsychotic depot and LAI comparative costs for 28 days treatment on ranging doses Drug Tariff Sep 2013 ( Doses quoted do not imply equivalence) Paliperidone 150mg/month Paliperidone 100mg/month Paliperidone 75mg/month Paliperidone 50mg/month Risperidone Consta 50mg/2w Risperidone Consta 37.5mg/2w Risperidone Consta 25mg/2w Pipotiazine (Piportil) 200mg/4w Pipotiazine (Piportil) 100mg/4w Pipotiazine (Piportil) 50mg/4w Fluphenazine (Modecate) 100mg/2w Zuclopenthixol (Clopixol) 600mg/1w Zuclopenthixol (Clopixol) 500mg/2w Zuclopenthixol (Clopixol) 200mg/2w Haloperidol (Haldol) 300mg/4w Haloperidol (Haldol) 50mg/4w Flupentixol (Depixol Conc) 300mg/2w Flupentixol (Depixol Conc) 50mg/4w Flupentixol (Depixol) 40mg/2w Flupentixol (Depixol) 20mg/2w Preferred APD depot 2nd line alternative APD LAI Page 5 of 6 5
6 Transfer of APD prescribing to GPs Patients must be stabilised on an APD before requesting the GP to take over prescribing responsibility. The following minimum information must be provided to enable the GP to safely take on the continued prescribing for the patient: Choice of APD: including formulation and dose. Rationale for choice of APD: if not a preferred choice, provide explanation as to why preferred choices are not appropriate and why second line alternative APD has been selected. Where relevant include details of APDs that have already been tried and why they were discontinued or not appropriate. Monitoring requirements: as per physical health policy. Date of next review Prescriber contact details: in case GP has any queries or concerns. Clinicians must ensure all the above information is included in correspondence to GPs to ensure the smooth and safe transfer of prescribing responsibility. References; NICE Clinical guideline 82 Schizophrenia 2009 SIGN 131 Management of Schizophrenia 2013 Psychotropic Drug Directory 2012, Stephen Bazire The Maudsley Prescribing Guidelines in Psychiatry 11 th Edition 2012 Drug Tariff - September 2013 Approved by HPFT DTC September 2013 Approved by HMMC September 2013 Approved by PCMMG November 2013 Review date: September 2015 or sooner if new evidence is published or if significant price changes occur. Page 6 of 6
SHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationFormulary Item Restrictions and/or Advice Site availability
Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine
More informationGuidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults
Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice
More informationDocument Title Antipsychotics Prescribing Guidelines for Schizophrenia
Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Description Document Type Prescribing Guidance Service Application Medicines Management Version 1.0 Policy Reference no.
More informationAntipsychotics. This factsheet covers -
Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder
More informationThis factsheet covers:
Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar
More informationTreatment of Schizophrenia Appendix Three Page 1 of 8
Prescribing Guidelines Treatment of Schizophrenia Scope of this guidance This guidance aims to describe the pharmacological management of schizophrenia at a simple and intermediate level, with a brief
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationMMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION
MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION Page 1 of 16 Table of Contents Why we need this Policy... 3 What the Policy is trying to do... 3 Which stakeholders have been involved
More informationPORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016
Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the
More informationHigh Dose Antipsychotic Therapy (HDAT) guideline
Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857
More informationLAI Antipsychotics Frequently Asked Questions
LAI Antipsychotics Frequently Asked Questions Click each question to see the answer. Click the link to return to this list. Who should receive LAIs (long acting injectable antipsychotics)? Which antipsychotics
More informationAntipsychotic Prescribing Audit:
Antipsychotic Prescribing Audit: Measuring the impact of a prescribing intervention Audit Co-ordinator/ Author of Report: Supervisor: Professor Shôn W Lewis Table of Contents List of Tables... 3 List of
More informationGUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)
GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationAntipsychotic Medication: Monitoring Side Effects
Antipsychotic Medication: Monitoring Side Effects Aims Review national practice guidelines and evidence regarding current standards of care. Discuss clinical implications of AP side effects. Reflect on
More informationAntipsychotics. BMF 84 - Antipsychotics
Antipsychotics BMF 84 - Antipsychotics Antipsychotic medications (neuroleptics) are used for the treatment of psychosis, mainly schizophrenia and manic depression (bipolar disorder). They reduce symptoms
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS Date 20 th November 2014 Our Ref HDAT_MGPG/Nov14 Enquiries to Caroline Hind Extension 56088 Direct Line 01224 556088 Email caroline.hind2@nhs.net
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationDEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING
DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING DECEMBER 2016 This policy supersedes all previous policies Policy title Depot Antipsychotic Medication: Guidelines for Prescribing
More informationDepots Improving patient care?
Depots Improving patient care? Caroline Parker Consultant Pharmacist NAPICU Conference 9 th September 2010 Depots Coercion Paternalistic Degrading Standard treatment Necessary Old fashioned Forced Easier
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationGuidance on the Use of Antipsychotic Long-acting Injections in North of England
Guidance on the Use of Antipsychotic Long-acting Injections in North of England This guidance aims to inform and support prescribers within the three mental health service providers in the north of England
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationPrescription of High Dose Antipsychotic Medication
Subject (M1) Title Medicine Prescription of High Dose Antipsychotic Medication Manual Mental Health Procedure No M1-P-2-MH Department Pharmacy Distribution All Author Rae McKnight Review 4 Reviewer Jonathan
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationNew Medicines Committee Briefing November 2011
New Medicines Committee Briefing November 2011 Paliperidone long-acting injection (Xeplion ) for schizophrenia Paliperidone palmitate long-acting injection (Xeplion ) is to be reviewed for use within:
More informationHigh Dose Antipsychotic Therapy (HDAT) guideline
Document level: Trustwide (TW) Code: MP18 Issue number: 4 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Authors details Michael Slater (Clinical Pharmacist, tel. 01625
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationHigh Dose Antipsychotic Medication Policy
High Dose Antipsychotic Medication Policy Policy Title State previous title where relevant State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For clinical policies
More informationGuidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version)
Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version) This guidance aims to inform and support prescribers within the three mental health service providers in the
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationA review of the efficacy and tolerability of antipsychotic long-acting injections
A review of the efficacy and tolerability of antipsychotic long-acting injections Allison Whyte MPharm-IP, Caroline Parker FFRPS, FRPharmS, FCMHP The formulation of long-acting injections (LAIs) as a method
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 List of medicines concerned: SECOND-GENERATION ORAL ANTIPSYCHOTICS SOLIAN 100 mg, 200 mg, 400 mg
More informationLurasidone In Vitro Receptor Binding
Lurasidone Lurasidone In Vitro Receptor Binding 5-HT 2A D 2 Log of Ki Values (nm) M 1 * 5-HT 7 5-HT 1A α 2C α H 1 * 2A 0.1 1 10 100 1000 10000 HIGH AFFINITY Dopamine D 2 Serotonin 5-HT 2A Serotonin 5-HT
More informationThis document has been produced in collaboration with the Lancashire Commissioning Support Unit
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019
More informationJoint Formulary for Psychotropic Medication.
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories
More informationWhat Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationPALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration
PALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration Paliperidone 1 monthly long acting injection (Xeplion ) This is included in the Trust medicines
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationSpecial Project. National Mental Health Benchmarking Project Forensic Forum. Seclusion Medication Audit
National Mental Health Benchmarking Project Forensic Forum Special Project Seclusion Medication Audit A joint Australian, State and Territory Government Initiative October 2007 National Benchmarking Project
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationClinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.
Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationClinician's Guide to Prescribing Depot Antipsychotics
Handout for the Neuroscience Education Institute (NEI) online activity: Clinician's Guide to Prescribing Depot Antipsychotics Learning Objectives Explain the benefits and risks of depot antipsychotics
More informationNational Center for Mental Health
National Center for Mental Health 9 de Febrero St., Mandaluyong City Telephone No.: 531-91 Organizational Structure Medical Center Chief II Chief, Medical and Professional Staff (Hospital Service) Chief,
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 November 2014 LATUDA 18.5 mg, film-coated tablet B/28 (CIP: 3400927887130) LATUDA 37 mg, film-coated tablet B/28
More informationNational Center for Mental Health
National Center for Mental Health 9 de Febrero St., Mandaluyong City Telephone No.: 531-9001 (c/o Dr. Vinluan) Organizational Structure Medical Center Chief II Chief, Medical and Professional Staff (Hospital
More informationPsychopharmacological treatment of first episode psychosis
Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center
More informationAntipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
More informationGuidance on the Use of Antipsychotics
Guidance on the Use of Antipsychotics Version 3 (October 2015) GUIDELINE NO RATIFYING DRUGS AND THERAPEUTICS GROUP COMMITTEE DATE RATIFIED DATE AVAILABLE ON INTRANET NEXT REVIEW DATE October 2017 ORIGINAL
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationMEDICINES MANAGEMENT TOOL FOR ANTIPSYCHOTICS
MEDICINES MANAGEMENT TOOL FOR ANTIPSYCHOTICS Document Reference G368 Version Number 4.0 Author/Lead Job Title Wendy Tucker Jackie Stark Alberto Ortiz-Moya Date last reviewed, (this version) August 2017
More informationLiterature Scan: Parenteral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDate 18/02/13 Our Ref I write in response to your request for information in relation to NHS Lothian s Formulary
Lothian NHS Board Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG Telephone 0131 536 9000 Fax 0131 536 9088 www.nhslothian.scot.nhs.uk Date 18/02/13 Our Ref 3560 Enquiries to Richard Mutch Extension
More informationMichael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationAntipsychotic medication in schizophrenia: a review
British Medical Bulletin, 2015, 114:169 179 doi: 10.1093/bmb/ldv017 Advance Access Publication Date: 8 May 2015 Antipsychotic medication in schizophrenia: a review John Lally, * and James H. MacCabe Department
More informationAT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE
AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Topic AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Scope 4.3.1 (a) Review question(s)
More informationRexulti (brexpiprazole)
Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia
More informationHOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationANTIPSYCHOTIC GUIDELINES
ANTIPSYCHOTIC GUIDELINES TREATMENT OF SCHIZOPHRENIA AND PSYCHOSIS Page 1 of 44 Authors: Ms Diane Booth, Chief Pharmacist,. Mrs Kiran Hewitt, Lead Clinical Pharmacist, Berkshire Healthcare NHS Foundation
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationFORMULARY AND PRESCRIBING GUIDELINES 2017
FORMULARY AND PRESCRIBING GUIDELINES 2017 1 Document Control Summary Issue Date Amended Section /page Author/ Amended by 1. Sept 06 All Jane Moriba Summary of Change Removed Trust policy and guideline
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationMental Health Subcommittee of PTAC meeting held 21 June (minutes for web publishing)
Mental Health Subcommittee of PTAC meeting held 21 June 2010 (minutes for web publishing) Mental Health Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationINJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM
SUBMIT TO Utilization Management Department Phone: 1.866.912.6285 Fax: 1.866.694.3649 MEMBER INFORMATION INJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM Fax completed form to Cepatico at 866.694.3649. Upon
More informationBirmingham and Solihull Mental Health NHS Foundation Trust. Formulary. March 2013
Birmingham and Solihull Mental Health NHS Foundation Trust Formulary March 2013 1 Table of contents Antipsychotics Introduction p3 1. Antipsychotics available p4 2. Mood stabilisers available p5 3. Prescribing
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationThe routine use of Intramuscular anticholinergics and depot antipsychotics BY DR. CHANTELLE MAGRI FOUNDATION YEAR 1
The routine use of Intramuscular anticholinergics and depot antipsychotics BY DR. CHANTELLE MAGRI FOUNDATION YEAR 1 Contributors Dr. Francesca Falzon Aquilina; BST psychiatry Dr Claire Axiaq; Resident
More informationCurrent Non-Preferred Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationasenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd
asenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationDrugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationMedicines Guideline: High-dose antipsychotic prescribing (MG01)
Medicines Guideline: High-dose antipsychotic prescribing (MG01) Document author Assured by Review cycle Ben Browning, Locality Lead Pharmacist (Secure Services) MOG sub-group (04.05.16) Review every two
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationChapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More information